Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04731610 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma (RADIO-RYTHMIC-01)

Study acronym: RADIO-RYTHMIC
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 20 to 21v13
  2. Start date: Dec 28, 2024 to Dec 28, 2021v12
  3. Primary completion date: Dec 28, 2028 to Dec 28, 2031v11 Show 4 more changesShow less
    • Start date: Dec 28, 2021 to Dec 28, 2024
    • Study completion date: Dec 28, 2029 to Dec 28, 2032
    • Eligibility criteria expanded, about 8 words
    • Site details revised at 1 of 20 sites
  4. Study title expanded, about 1 wordv10
  5. Primary completion date: Feb 1, 2025 to Dec 28, 2028
    • Study sites: 18 to 20
    • Study completion date: Mar 1, 2029 to Dec 28, 2029
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Re-verified, no change to tracked fieldsv8
  2. Site details revised at 4 of 18 sitesv7
  3. Study sites revised (18)v6
  4. Study sites revised (18)v5
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2, 2021 to Dec 28, 2021
    • Study sites: 17 to 18
    v4
  6. Start date: Apr 2, 2021 to Jul 2, 2021
    • Study sites: 15 to 17
    v3
  7. Start date: Mar 2, 2021 to Apr 2, 2021
    • Eligibility criteria revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Curie
43 trials monitored
See 1 trial at risk
The primary objective of the study : to compare the Recurrence-Free survival (RFS) between arms. RFS is defined as time from randomisation to the first recurrence (either local-regional or distant) or death of any cause.
Trial Details
NCT Number NCT04731610
Lead Sponsor Institut Curie
Conditions
(from sponsor)		 Thymoma Malignant Recurrent
Enrollment 314 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov